Clinical Trial Update: Efficacy and Safety Study of Ontamalimab as Induction Therapy in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 305) [Phase 3]

View source ↗

Summary

Phase 3 trial of ontamalimab as induction therapy for moderate-to-severe Crohn's disease terminated; results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease

Drugs mentioned

• Ontamalimab (ontamalimab)

Snippet

Sponsor: Shire | Conditions: Crohn's Disease | Phase 3 | Status: TERMINATED | Results posted: 2021-04-29